Vistagen's Fasedienol Shows Positive Long-Term Efficacy in Social Anxiety Disorder Trial
Event summary
- Vistagen reported preliminary positive data from the open-label extension (OLE) portion of its PALISADE-3 Phase 3 study of fasedienol for social anxiety disorder, showing well-tolerated safety and clinically relevant efficacy improvements over four months.
- Mean LSAS score improvement reached 25.4 points at Month 4, with 56% of subjects achieving a ≥20 point improvement.
- SPIN score improvement reached 12.4 points at Month 4, with 55% of subjects achieving a ≥10 point improvement.
- The study involved 341 subjects using fasedienol as needed, up to six times daily, for up to 12 months.
The big picture
Vistagen's positive OLE data for fasedienol comes at a critical juncture for the biopharmaceutical company, as it seeks to differentiate its intranasal product candidates in the competitive mental health treatment landscape. The results suggest potential clinical meaningfulness, but the path to regulatory approval remains uncertain following the earlier mixed outcomes from the randomized portion of PALISADE-3. The broader industry is watching closely, as Vistagen's nose-to-brain neurocircuitry approach could redefine treatment paradigms if successful.
What we're watching
- Regulatory Pathway
- Whether the positive OLE data will support a potential New Drug Application (NDA) submission to the FDA, given the earlier mixed results from the randomized portion of PALISADE-3.
- Clinical Validation
- The pace at which Vistagen can generate additional evidence to support the clinical meaningfulness of fasedienol's duration and magnitude of effect.
- Market Differentiation
- How Vistagen positions fasedienol as a safer alternative to existing pharmacological options for social anxiety disorder, leveraging its nose-to-brain neurocircuitry approach.
Related topics